PTGS2 and Behcet disease: Amirnia et al. further confirmed elevated COX-2 levels in both malignant (SCC, BCC) and pre-malignant (BD, AK) lesions, suggesting that COX-2 could serve as a molecular target for treating various skin tumors [49,50].